LEADER 04019nam  2201045z- 450 
001 9910595079403321
005 20220916
035   $a(CKB)5680000000080731
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/92076
035   $a(oapen)doab92076
035   $a(EXLCZ)995680000000080731
100   $a20202209d2022      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aEnhancing Mesenchymal Stem Cells (MSCs) for Therapeutic Purposes
210   $aBasel$d2022
215   $a1 online resource (204 p.)
311 08$a3-0365-4996-X 
311 08$a3-0365-4995-1 
330   $aThe regenerative and immunomodulatory properties of mesenchymal stem cells (MSCs) have made these cells the focus of multiple pre-clinical studies and clinical trials. While the results from these clinical studies have established that MSCs are safe, the efficacy of these cells is not as well-established. In this regard, there have been increased efforts towards generating potentiated/activated MSCs with enhanced therapeutic efficacy. Research on the mechanisms for enhancing MSC potency and efficacy is an area of active study with great potential for translation into clinical settings. The purpose of this book is to bring together recent research from a broad range of topics relating to potentiation strategies for enhancing MSC therapeutic efficacy, including growth factor pre-conditioning, hypoxia, and 3D culture. The research compiled in this book increases the basic understanding of MSC culture techniques and describes some MSC preparations for potential novel therapeutic applications.
517   $aEnhancing Mesenchymal Stem Cells 
606   $aMedicine and Nursing$2bicssc
610   $a3-methyladenine
610   $a3D culture
610   $aadipose tissue-derived stem cells (ASCs)
610   $aadipose-derived stem cell
610   $aAKB-6548
610   $aangiogenesis
610   $aastrocytes
610   $aautophagy
610   $aaxon growth
610   $aCD206
610   $acell therapy
610   $achemotaxis
610   $acombination therapy
610   $aengineered cardiac patches
610   $aexosome
610   $afibroblast growth factor 2
610   $ahepatocyte growth factor
610   $ahypoxia
610   $aIFN-?
610   $aimmunomodulation
610   $aimmunosuppression
610   $aiMSC secretome
610   $ainflammation
610   $aiPSC-derived MSCs
610   $aliver cirrhosis
610   $amacrophages
610   $amalignant pleural mesothelioma (MPM)
610   $amesenchymal stem cells
610   $amesenchymal stromal cells
610   $amesothelioma
610   $ananofiber-hydrogel composite
610   $aneural
610   $aneuroprotection
610   $aneurospheres
610   $aosteogenic differentiation
610   $aoxygen conditions
610   $aparacrine potential
610   $aphagocytosis
610   $aplacenta-derived mesenchymal stem cells
610   $apluripotency
610   $apolyunsaturated fatty acid
610   $apotentiation of iMSC efficacy
610   $apre-conditioning
610   $apreconditioning
610   $apriming
610   $aquiescence
610   $arapamycin
610   $asecondary injury
610   $asecretome
610   $asecretory profile
610   $aspheroids
610   $aspinal cord injury
610   $aumbilical cord
610   $aVadadustat
610   $aWharton's jelly mesenchymal stem cells
610   $aWKYMVm
615  7$aMedicine and Nursing
700   $aYlostalo$b Joni H$4edt$01289237
702   $aDurand$b Nisha C$4edt
702   $aYlostalo$b Joni H$4oth
702   $aDurand$b Nisha C$4oth
906   $aBOOK
912   $a9910595079403321
996   $aEnhancing Mesenchymal Stem Cells (MSCs) for Therapeutic Purposes$93030230
997   $aUNINA